Revolution Medicines, Inc. (RVMD): Total Liabilities
$723.21M
As of 2025-12-31
$1.72B
As of 2026-06-30
+78.7%
3-year compound annual growth
+50.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $723.21M | +146.7% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $293.10M | +24.5% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $235.51M | +85.8% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $126.74M | -6.4% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $135.42M | +46.0% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $92.72M | +36.4% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $67.99M | n/a | 2021-03-02, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $723.21M | +146.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $11.18B | -1.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
Compare RVMD, VXRT, RGEN, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗